Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones

Clinical and Experimental Metastasis

Volumn 14, Issue 2, 1996, Pages 95-106

  Van Golen, K L ^a   Risin, S ^a   Staroselsky, A ^a   Berger, D ^a   Tainsky, M A ^a   Pathak, S ^a   Price, J E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chromosomes; Metastatic melanoma; p53; Somatic cell hybrids

Indexed keywords

ANIMAL CELL; ARTICLE; CELL FUSION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYBRID CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MELANOMA; METASTASIS; MOUSE;

ANIMALS; BASE SEQUENCE; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 17; DNA PRIMERS; GENES, DOMINANT; GENES, P53; HUMANS; HYBRID CELLS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; MONOMERIC GTP-BINDING PROTEINS; NEOPLASM METASTASIS; NUCLEOSIDE-DIPHOSPHATE KINASE; PHENOTYPE; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0029978028     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00121206     Document Type: Article

References (68)

1. Fidler IJ, 1992, The biology of melanoma and metastasis. In: Balch CM, Houghton AN, Milton GW, Sober AJ, and Soong S, eds. Cutaneous Melanoma, 2nd edn. Philadelphia: J.B. Lippincott, pp. 112-29.
2. 125I-5-iodo-2′deoxyuridine. J Natl Cancer Inst, 45, 773-82.
3. Weiss L, 1982, Metastatic inefficiency. In: Liotta LA, Hart IR, eds. Tumor Invasion and Metastasis. Boston: Nijhoff, pp. 81-98.
4. Aukerman SL, Price JE and Fidler IJ, 1986, Different deficiencies in prevention of tumorigenic-low-metastatic murine K-1735b melanoma cells from producing metastases. J Natl Cancer Inst, 77, 915-21.
5. Fidler IJ, 1984, The Ernst W. Bertner Memorial Award Lecture: The evolution of biological heterogeneity in metastatic neoplasms. In: Nicolson G, Milas L, eds. Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects. New York: Raven Press, pp. 5-26.
6. Poste G and Fidler IJ, 1980, The pathogenesis of cancer metastasis. Nature, 283, 139-46.
7. Nicolson GL, 1991, Molecular mechanisms of cancer metastasis: tumor and host properties and the role of oncogenes and suppressor genes. Curr Opin Oncol, 3, 75-92.
8. Kerbel RS, Waghorne C, Korczak B, Lagarde A and Breitman M, 1988, Clonal dominance of primary tumors by metastatic cells: genetic analysis and biological implications. Cancer Surv, 7, 597-629.
9. Cifone MA and Fidler IJ, 1981, Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci USA, 78, 6949-52.
10. Kerbel RS, 1990, Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res, 55, 87-132.
11. Fidler IJ, Gruys E, Cifone MA, Barnes Z and Bucana C, 1981, Demonstration of multiple phenotypic diversity in a murine melanoma of recent origin. J Natl Cancer Inst, 67, 947-56.
12. Staroselsky AH, Pathak S, Chernajovsky Y, Tucker SL and Fidler IJ, 1991, Predominance of the metastatic phenotype in somatic cell hybrids of the K-1735 murine melanoma. Cancer Res, 51, 6292-8.
13. Kripke ML, 1979, Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J Natl Cancer Inst, 63, 541-8.
14. Li L, Price JE, Fan D, Zhang RD, Bucana CD and Fidler IJ, 1989, Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites. J Natl Cancer Inst, 81, 1406-12.
15. Pathak S, 1976, Chromosome banding techniques. J Reprod Med, 17, 25-8.
16. Volbereg T, Zick Y, Dror R, et al. 1992, The effect of tyrosine-specific protein phosphorylation on the assembly of adherens-type junctions. EMBO J, 11, 1733-42.
17. Laemmli UK, 1970, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-5.
18. Lowe SW and Riley HE, 1993, Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Develop, 7, 535-45.
19. Kanjilal S, Pierceall WE, Cummings KK, Kripke ML and Ananthaswamy HN, 1993, High frequency of p53 mutations in ultraviolet radiation-induced murine skin tumors: evidence for strand bias and tumor heterogeneity. Cancer Res, 53, 2961-4.
20. Nicolson GL, Gallick GE, Spolin WH, Lembo TM and Tainsky MA, 1992, Transfection of activated c-h-ras EJ/pSV2neo or pSV2neo genes into rat mammary cells: rapid stimulation of clonal diversification of spontaneous metastatic and cell surface properties, Oncogene, 7, 1127-35.
21. Kerbel RS, Waghorne C, Man MS, Elliot B and Breitman ML, 1987, Alteration of the tumorigenic and metastatic properties of neoplastic cells is associated with the process of calcium phosphate-mediated DNA transfection. Proc Natl Acad Sci USA, 84, 1263-7.
22. Weiss MC and Green H, 1967, Human-mouse hybrid cell lines containing partial complements of human chromosomes and functioning human genes. Proc Natl Acad Sci USA, 58, 1104-11.
23. Steeg PS, Bevilacqua G, Koppler L, et al. 1988, Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst, 80, 200-4.
24. Leone A, McBride OW, Weston A, et al. 1991, Somatic allelic deletion of nm23 in human cancer. Cancer Res, 51, 2490-3.
25. Stretch JR, Gatter KC, Ralfkiaer, Lane DP and Harris AL, 1991, Expression of mutant p53 in melanoma. Cancer Res, 51, 5976-9.
26. Volkenandt M, Schlegel U, Nanus DM and Albino A, 1991, Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res, 4, 35-40.
27. Akslen LA and Mørkve O, 1992, Expression of p53 in cutaneous melanoma. Int J Cancer, 52, 13-16.
28. Critofolini M, Boi S, Girlando S, et al. 1993, p53 protein expression in nevi and melanomas. Arch Dermatol, 129, 739-43.
29. McGregor JM, Yu CC-W, Dublin EA, Barnes DM, Levison DA and MacDonald DM, 1993, p53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br J Dermatol, 128, 606-11.
30. Weiss J, Schwechheimer K, Cavenee WK, Herlyn M and Arden K, 1993, Mutation and expression of the p53 gene in malignant melanoma cells. Int J Cancer, 54, 693-9.
31. Lassam NJ, From L and Kahn H, 1993, Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res, 53, 2235-8.
32. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science, 235, 177-82.
33. Eul J, Gronemeyer H, Adolph S and Hameister H, 1988, Suppression of tumorigenicity in T-cell lymphoma hybrids is correlated with changes in myc expression and DNA replication of the myc chromosomal domain. Chromosoma, 96, 248-54.
34. Schafer R, Nirko AC, Ambuhl PM and Grzeschik KH, 1991, Evidence for human DNA-mediated transfer of the suppressed phenotype into malignant Chinese hamster cells. Oncogene, 6, 2221-8.
35. Saltman D, Ross JA, Gordon JM, et al. 1989, Suppression of malignancy in human lymphoid cell hybrids: the role of differentiation. J Cell Sci, 94, 743-56.
36. Pickford I and Franks LM, 1988, Genetic aspects of tumor metastasis. In: Franks LM, ed. Cancer Surveys. Oxford: Oxford University Press, Vol 7, pp. 351-71.
37. Ichikawa T, Ichikawa Y, Dong J, et al. 1992, Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res, 52, 3486-90.
38. Ichikawa T, Niheei N, Suzuki H, et al. 1994, Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8. Cancer Res, 54, 2299-302.
39. Rinker-Schaeffer CW, Hawkins AL, Ru N, et al. 1994, Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res, 54, 6249-56.
40. Welch DR, Chen P, Miele ME, et al. 1994, Microcell-mediated transfer of chromosome 6 into metastastic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. Oncoyene, 9, 255-62.
41. Collard JG, van de Poli M, Scheffer A, et al. 1987, Location of genes involved in invasion and metastasis on human chromosome 7. Cancer Res, 47, 6666-70.
42. Ito M, Izahura M, Shimizu K and Sekiguchi M, 1994, Metastatic phenotype in hybrid cells derived from B16 melanoma. Cancer Lett, 78, 33-9.
43. Radinsky R, Weisberg HZ, Staroselsky AN and Fidler IJ, 1992, Expression level of the nm23 gene in clonal populations of metastatic murine and human neoplasms. Cancer Res, 52, 5808-14.
44. Leach RJ, Thayer MJ, Schafer AJ and Fournier REK, 1989, Physical mapping of human chromosome 17 using fragment-containing microcell hybrids. Genomics, 5, 167-76.
45. NIH/CEPH Collaborative Mapping Group, 1992, A comprehensive genetic linkage map of the human genome. Science, 258, 67-86.
46. Hynes RO, 1992, Integrins: versatility, modulation, and signaling in cell adhesion. Cell, 69, 11-25.
47. 3 subunit with tumor progression. Cancer Res, 50, 6757-64.
48. Hart IR, Birch M and Marshall JF, 1991, Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev, 10, 115-28.
49. Fearon ER and Vogelstein B, 1990, A genetic model for colorectal tumorigenesis. Cell, 62, 759-67.
50. Kastan MB, Onyekwere O, Siransky D, Vogelstein B and Craig RW, 1991, Participation of p53 protein in the cellular response to DNA damage. Cancer Res, 51, 6304-11.
51. Kastan MB, Zhan Q, El-Diery WS, et al. 1992, A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71, 587-97.
52. Yonisch-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, and Oren M, 1991, Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature, 352, 345-7.
53. Merrit AJ, Potten CS, Kemp CJ, et al. 1994, The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res, 54, 614-7.
54. Nigro JM, Baker SJ, Preisinger AC, et al. 1989, Mutations in the p53 gene occur in diverse human tumor types. Nature, 342, 705-8.
55. MacGeoch C, Barnes DM, Newton JA, et al. 1993, p53 protein detected by immunohistochemical staining is not always mutant. Dis Markers, 11, 239-50.
56. Luca M, Lenzi R, Jackson-Lee D, Gutman M, Fidler IJ, and Bar-Eli M, 1993, p53 mutations are infrequent and do not correlate with the metastatic potential of human melanoma cells. Int J Oncol, 3, 19-22.
57. Price JE, Aukerman SL and Fidler IJ, 1986, Evidence that the process of murine melanoma metastasis is sequential and selective and contains stochastic elements. Cancer Res, 46, 5172-8.
58. Li L, Kilbourn RG, Adams J and Fidler IJ, 1991, Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Res, 51, 2531-5.
59. Dong Z, Staroselsky AH, Xiaoxia Q, Xie K and Fidler IJ, 1994, Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastases in K-1735 murine melanoma cells. Cancer Res, 54, 789-93.
60. Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS and Tannenbaum SR, 1992, DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA, 89, 3030-4.
61. Nelson WG and Kastan MB, 1994, DNA strand breaks: the DNA template alteration that triggers p53-dependent DNA damage response pathways. Mol Cell Biol, 14. 1815-23.
62. Michalovitz D, Halevy O and Oren M, 1991, p53 mutations: gains or losses? J Cell Biochem, 45, 22-9.
63. Martinez J, Georgoff I, Martinez J and Levine AJ, 1991, Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev, 5, 151-9.
64. Donehower LA, 1994, Tumor suppressor gene p53 and apoptosis. Cancer Bull, 46, 161-6.
65. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD, 1992, Altered cell arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70, 923-35.
66. Knudson AG, 1993, Antioncogenes and human cancer. Proc Natl Acad Sci USA, 90, 10914-21.
67. Yin Y, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM, 1992, Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70, 937-48.
68. Schimke RT, 1988, Gene amplification in cultured cells. J Biol Chem, 263, 5989-92.